Mechanisms of disease: Parvovirus B19

New England Journal of Medicine

Volumn 350, Issue 6, 2004, Pages 586-597

  Young, Neal S ^a,b   Brown, Kevin E ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; IMMUNOGLOBULIN; PROTEIN VP1; RECOMBINANT ANTIGEN;

ANEMIA; APLASTIC ANEMIA; ARTHROPATHY; ERYTHEMA INFECTIOSUM; FETUS HYDROPS; GENETIC TRANSCRIPTION; HUMAN; PARVOVIRUS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; DISEASE TRANSMISSION; GENETICS; ULTRASTRUCTURE; VIROLOGY; VIRUS GENOME; VIRUS INFECTION;

DISEASE TRANSMISSION, VERTICAL; ERYTHEMA INFECTIOSUM; GENOME, VIRAL; HUMANS; HYDROPS FETALIS; PARVOVIRIDAE INFECTIONS; PARVOVIRUS B19, HUMAN;

EID: 1442334131     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMra030840     Document Type: Review

References (126)

1. Cossart YE, Field AM, Cant B, Widdows D. Parvovirus-like particles in human sera. Lancet 1975;1:72-3.
2. Pattison JR, Jones SE, Hodgson J, et al. Parvovirus infections and hypoplastic crisis in sickle cell anaemia. Lancet 1981;1:664-5.
3. Anderson MJ, Lewis E, Kidd IM, Hall SM, Cohen BJ. An outbreak of erythema infectiosum associated with human parvovirus infection. J Hyg (London) 1984;93:85-93.
4. Anand A, Gray ES, Brown T, Clewley JP, Cohen BJ. Human parvovirus infection in pregnancy and hydrops fetalis. N Engl J Med 1987;316:183-6.
5. Kurtzman G, Frickhofen N, Kimball J, Jenkins DW, Nienhuis AW, Young NS. Pure red-cell aplasia of 10 years' duration due to persistent parvovirus B19 infection and its cure with immunoglobulin therapy. N Engl J Med 1989;321:519-23.
6. Anderson LJ, Young NS, eds. Human parvovirus B19. Vol. 20 of Monographs in virology. Basel, Switzerland: Karger, 1997.
7. Bloom ME, Young NS. Parvoviruses. In: Knipe DM, Howley PM, eds. Fields virology. Philadelphia: Lippincott Williams & Wilkins, 2001:2361-79.
8. Heegaard ED, Brown KE. Human parvovirus B19. Clin Microbiol Rev 2002;15:485-505.
9. Verge J, Cristoforoni N. La gastroentérite infectieuse des chats est-elle due a un virus filtrable? C R Soc Biol 1928;99:312-4.
10. Parrish CR. Pathogenesis of feline panleukopenia virus and canine parvovirus. Baillieres Clin Haematol 1995;8:57-71.
11. Bloom ME, Kanno H, Mori S, Wolfinbarger JB. Aleutian mink disease: puzzles and paradigms. Infect Agents Dis 1994;3:279-301.
12. Molitor TW, Joo HS. Clinical and pathological features of porcine-parvovirus-related disease and its diagnosis. In: Tijssen P, ed. CRC handbook of parvoviruses. Vol. 2. Boca Raton, Fla.: CRC Press, 1990:135-50.
13. Muzyczka N, Berns KI. Parvoviridae: the viruses and their replication. In: Knipe DM, Howley PM, eds. Fields virology. Philadelphia: Lippincott Williams & Wilkins, 2001:2327-59.
14. Brown KE, Young NS. The simian parvoviruses. Rev Med Virol 1997;7:211-8.
15. Shade RO, Blundell MC, Cotmore SF, Tattersall P, Astell CR. Nucleotide sequence and genome organization of human parvovirus B19 isolated from the serum of a child during a plastic crisis. J Virol 1986;58:921-36.
16. Fauquet CM, van Regenmortel MHV, Bishop DHL. Virus taxonomy deluxe: classification and nomenclature of viruses: seventh report of the International Committee on Taxonomy of Viruses. San Diego, Calif.: Academic Press, 2001.
17. Cotmore SF, Tattersall P. Characterization and molecular cloning of a human parvovirus genome. Science 1984;226:1161-5.
18. Nguyen QT, Sifer C, Schneider V, et al. Novel human erythrovirus associated with transient aplastic anemia. J Clin Microbiol 1999;37:2483-7.
19. Nguyen QT, Wong S, Heegaard ED, Brown KE. Identification and characterization of a second novel human erythrovirus variant, A6. Virology 2002;301:374-80.
20. Tsao J, Chapman MS, Agbandje M, et al. The three-dimensional structure of canine parvovirus and its functional implications. Science 1991;251:1456-64.
21. Chipman PR, Agbandje-McKenna M, Kajigaya S, et al. Cryo-electron microscopy studies of empty capsids of human parvovirus B19 complexed with its cellular receptor. Proc Natl Acad Sci U S A 1996;93:7502-6.
22. Ozawa K, Ayub J, Kajigaya S, Shimada T, Young NS. The gene encoding the nonstructural protein of B19 (human) parvovirus may be lethal in transfected cells. J Virol 1988;62:2884-9.
23. Moffatt S, Yaegashi N, Tada K, Tanaka N, Sugamura K. Human parvovirus B19 nonstructural (NS1) protein induces apoptosis in erythroid lineage cells. J Virol 1998;72:3018-28.
24. Schwarz TF, Gurtler LG, Zoulek G, Deinhardt F, Roggendorf M. Seroprevalence of human parvovirus B19 infection in Sao Tome and Principe, Malawi and Mascarene Islands. Zentralbl Bakteriol 1989;271:231-6.
25. de Freitas RB, Wong D, Boswell F, et al. Prevalence of human parvovirus (B19) and rubella virus infections in urban and remote rural areas in northern Brazil. J Med Virol 1990;32:203-8.
26. Risks associated with human parvovirus B19 infection. MMWR Morb Mortal Wkly Rep 1989;38:81-8, 93-7.
27. Human parvovirus B19 infections in United Kingdom 1984-86. Lancet 1987;1:738-9.
28. Chorba TL, Coccia P, Holman RC, et al. The role of parvovirus B19 in aplastic crisis and erythema infectiosum (fifth disease). J Infect Dis 1986;154:383-93.
29. Bell LM, Naides SJ, Stoffman P, Hodinka RL, Plotkin SA. Human parvovirus B19 infection among hospital staff members after contact with infected patients. N Engl J Med 1989;321:485-91.
30. Azzi A, Morfini M, Mannucci PM. The transfusion-associated transmission of parvovirus B19. Transfus Med Rev 1999;13:194-204.
31. Brown KE, Young NS, Alving BM, Barbosa LH. Parvovirus B19: implications for transfusion medicine: summary of a workshop. Transfusion 2001;41:130-5.
32. Woolf AD, Campion GV, Chishick A, et al. Clinical manifestations of human parvovirus B19 in adults. Arch Intern Med 1989;149:1153-6.
33. Anderson MJ, Higgins PG, Davis LR, et al. Experimental parvoviral infection in humans. J Infect Dis 1985;152:257-65.
34. Saarinen UM, Chorba TL, Tattersall P, et al. Human parvovirus B19-induced epidemic acute red cell aplasia in patients with hereditary hemolytic anemia. Blood 1986;67:1411-7.
35. Moore TL. Parvovirus-associated arthritis. Curr Opin Rheumatol 2000;12:289-94.
36. Kerr JR. Pathogenesis of human parvovirus B19 in rheumatic disease. Ann Rheum Dis 2000;59:672-83.
37. Naides SJ. Rheumatic manifestations of parvovirus B19 infection. Rheum Dis Clin North Am 1998;24:375-401.
38. Reid DM, Reid TMS, Brown T, Rennie JAN, Eastmond CJ. Human parvovirus-associated arthritis: a clinical and laboratory description. Lancet 1985;1:422-5.
39. White DG, Woolf AD, Mortimer PP, Cohen BJ, Blake DR, Bacon PA. Human parvovirus arthropathy. Lancet 1985;1:419-21.
40. Nikkari S, Luukkainen R, Möttönen T, et al. Does parvovirus B19 have a role in rheumatoid arthritis? Ann Rheum Dis 1994;53:106-11.
41. Speyer I, Breedveld FC, Dijkmans BAC. Human parvovirus B19 infection is not followed by inflammatory joint disease during long term follow-up: a retrospective study of 54 patients. Clin Exp Rheumatol 1998;16:576-8.
42. Kerr JR, Cartron JP, Curran MD, Moore JE, Elliott JRM, Mollan RAB. A study of the role of parvovirus B19 in rheumatoid arthritis. Br J Rheumatol 1995;34:809-13.
43. Soderlund M, von Essen R, Haapasaari J, Kiistala U, Kiviluoto O, Hedman K. Persistence of parvovirus B19 DNA in synovial membranes of young patients with and without chronic arthropathy. Lancet 1997;349:1063-5.
44. Takahashi Y, Murai C, Shibata S, et al. Human parvovirus B19 as a causative agent for rheumatoid arthritis. Proc Natl Acad Sci U S A 1998;95:8227-32.
45. Mimori A, Misaki Y, Hachiya T, Ito K, Kano S. Prevalence of antihuman parvovirus B19 IgG antibodies in patients with refractory rheumatoid arthritis and polyarticular juvenile rheumatoid arthritis. Rheumatol Int 1994;14:87-90.
46. Lehmann HW, von Landenberg P, Modrow S. Parvovirus B19 infection and autoimmune disease. Autoimmun Rev 2003;2:218-23.
47. Tanaka A, Sugawara A, Sawai K, Kuwahara T. Human parvovirus B19 infection resembling systemic lupus erythematosus. Intern Med 1998;37:708-10.
48. Leventhal NJ, Naides SJ, Freundlich B. Fibromyalgia and parvovirus infection. Arthritis Rheum 1991;34:1319-24.
49. Landenberg P, Lehmann HW, Knoll A, Dorsch S, Modrow S. Antiphospholipid antibodies in pediatric and adult patients with rheumatic disease are associated with parvovirus B19 infection. Arthritis Rheum 2003;48:1393-47.
50. Powars D. Aplastic anemia secondary to glue sniffing. N Engl J Med 1965;273:700-2.
51. Serjeant GR, Topley JM, Mason K, et al. Outbreak of aplastic crises in sickle cell anaemia associated with parvovirus-like agent. Lancet 1981;2:595-7.
52. Serjeant BE, Hambleton RR, Kerr S, Kilty CG, Serjeant GR. Haematological response to parvovirus B19 infection in homozygous sickle-cell disease. Lancet 2001;358:1779-80.
53. Smith-Whitley K, Zhao H, Hodinka RL, et al. Epidemiology of human parvovirus B19 in children with sickle cell disease. Blood 2004;103:422-7.
54. Saunders PWG, Reid MM, Cohen BJ. Human parvovirus induced cytopenias: a report of five cases. Br J Haematol 1986;63:407-10.
55. Pont J, Puchhammer-Stöckl E, Chott A, et al. Recurrent granulocytic aplasia as clinical presentation of a persistent parvovirus B19 infection. Br J Haematol 1992;80:160-5.
56. Barlow GD, McKendrick MW. Parvovirus B19 causing leucopenia and neutropenia in a healthy adult. J Infect 2000;40:192-5.
57. Bux J, Behrens G, Jaeger G, Welte K. Diagnosis and clinical course of autoimmune neutropenia in infancy: analysis of 240 cases. Blood 1998;91:181-6.
58. Osaki M, Matsubara K, Iwasaki T, et al. Severe aplastic anemia associated with human parvovirus B19 infection in a patient without underlying disease. Ann Hematol 1999;78:83-6.
59. Quian XH, Zhang GC, Jiao XY, et al. Aplastic anemia associated with parvovirus B19 infection. Arch Dis Child 2002;87:436-7.
60. Koch WC, Massey G, Russell CE, Adler SP. Manifestations and treatment of human parvovirus B19 infection in immunocompromised patients. J Pediatr 1990;116:355-9.
61. Hoang MP, Dawson DP, Rogers ZR, Scheuermann RH, Rogers BB. Polymerase chain reaction amplification of archival material for Epstein-Barr virus, cytomegalovirus, human herpesvirus 6, and parvovirus B19 in children with bone marrow hemophagocytosis. Hum Pathol 1998;29:1074-7.
62. Shirono K, Tsuda H. Parvovirus B19-associated haemophagocytic syndrome in healthy adults. Br J Haematol 1995;89:923-6.
63. Kurtzman G, Cohen B, Meyers P, Amunullah A, Young NS. Persistent B19 parvovirus infection as a cause of severe chronic anaemia in children with acute lymphocytic leukaemia. Lancet 1988;2:1159-62.
64. Heegaard ED, Schmiegelow K. Serologic study on parvovirus B19 infection in childhood acute lymphoblastic leukemia during chemotherapy: clinical and hematologic implications. J Pediatr Hematol Oncol 2002;24:368-73.
65. Frickhofen N, Abkowitz J, Safford M, et al. Persistent parvovirus infection in patients infected with human immunodeficiency virus type 1 (HIV-1): a treatable cause of anemia in AIDS. Ann Intern Med 1990;113:926-33.
66. Abkowitz JL, Brown KE, Wood RW, Kovach NL, Green SW, Young NS. Clinical relevance of parvovirus B19 as a cause of anemia in patients with human immunodeficiency virus infection. J Infect Dis 1997;176:269-73.
67. Levy R, Weissman A, Blomberg G, Hagay ZJ. Infection by parvovirus B 19 during pregnancy: a review. Obstet Gynecol Surv 1997;52:254-9.
68. Alger LS. Toxoplasmosis and parvovirus B19. Infect Dis Clin North Am 1997;11:55-75.
69. Morey AL, Keeling JW, Porter HJ, Fleming KA. Clinical and histopathological features of parvovirus B19 infection in the human fetus. Br J Obstet Gynaecol 1992;99:566-74.
70. Forestier F, Tissot JD, Vial Y, Daffos F, Hohlfeld P. Haematological parameters of parvovirus B19 infection in 13 fetuses with hydrops foetalis. Br J Haematol 1999;104:925-7.
71. Miller E, Fairley CK, Cohen BJ, Seng C. Immediate and long term outcome of human parvovirus B19 infection in pregnancy. Br J Obstet Gynaecol 1998;105:174-8.
72. Rodis JF, Quinn DL, Gary GW Jr, et al. Management and outcomes of pregnancies complicated by human B19 parvovirus infection: a prospective study. Am J Obstet Gynecol 1990;163:1168-71.
73. Jordan JA. Identification of human parvovirus B19 infection in idiopathic nonimmune hydrops fetalis. Am J Obstet Gynecol 1996;174:37-42.
74. Skjoldebrand-Sparre L, Tolfvenstam T, Papadogiannakis N, Wahren B, Broliden K, Nyman M. Parvovirus B19 infection: association with third-trimester intrauterine fetal death. BJOG 2000;107:476-80.
75. Valeur-Jensen AK, Pedersen CB, Westergaard T, et al. Risk factors for parvovirus B19 infection in pregnancy. JAMA 1999;281:1099-105.
76. Brown KE, Green SW, Antunez de Mayolo J, et al. Congenital anemia after transplacental B19 parvovirus infection. Lancet 1994;343:895-6.
77. Török TJ. Unusual clinical manifestations reported in patients with parvovirus B19 infection. In: Anderson LJ, Young NS, eds. Human paivovirus B19. Vol. 20 of Monographs in virology. Basel, Switzerland: Karger, 1997:61-92.
78. Cassinotti P, Siegl G, Michel BA, Brühlmann P. Presence and significance of human parvovirus B19 DNA in synovial membranes and bone marrow from patients with arthritis of unknown origin. J Med Virol 1998;56:199-204.
79. Wong S, Young NS, Brown KE. Prevalence of parvovirus B19 in liver tissue: no association with fulminant hepatitis or hepatitis-associated aplastic anemia. J Infect Dis 2003;187:1581-6.
80. Sokal EM, Melchior M, Cornu C, et al. Acute parvovirus B19 infection associated with fulminant hepatitis of favourable prognosis in young children. Lancet 1998;352:1739-41.
81. Notari EP, Orton SL, Cable RG, et al. Seroprevalence of known and putative hepatitis markers in United States blood donors with ALT levels at least 120 IU per L. Transfusion 2001;41:751-5.
82. He Z, Zhuang H, Wang X, et al. Retrospective analysis of non-A-E hepatitis: possible role of hepatitis B and C virus infection. J Med Virol 2003;69:59-65.
83. Arista S, De Grazia S, Di Marco V, Di Stefano R, Craxi A. Parvovirus B19 and "cryptogenic" chronic hepatitis. J Hepatol 2003;38:375-6.
84. Langnas AN, Markin RS, Cattral MS, Naides J. Parvovirus B19 as a possible causative agent of fulminant liver failure and associated aplastic anemia. Hepatology 1995;22:1661-5.
85. Dettmeyer R, Kandolf R, Baasner A, Banaschak S, Eis-Hubinger AM, Madea B. Fatal parvovirus B19 myocarditis in an 8-year-old boy. J Forensic Sci 2003;48:183-6.
86. Beghetti M, Gervaix A, Haenggeli CA, Berner M, Rimensberger PC. Myocarditis associated with parvovirus B19 infection in two siblings with merosin-deficient congenital muscular dystrophy. Eur J Pediatr 2000;159:135-6.
87. Saint-Martin J, Choulot JJ, Bonnaud E, Morinet F. Myocarditis caused by parvovirus. J Pediatr 1990;116:1007-8.
88. Nigro G, Bastianon V, Colloridi V, et al. Human parvovirus B19 infection in infancy associated with acute and chronic lymphocytic myocarditis and high cytokine levels: report of 3 cases and review. Clin Infect Dis 2000;31:65-9.
89. Schowengerdt KO, Ni J, Denfield SW, et al. Association of parvovirus B19 genome in children with myocarditis and cardiac allograft rejection: diagnosis using the polymerase chain reaction. Circulation 1997;96:3549-54.
90. Pankuweit S, Moll R, Baandrup U, Portig I, Hufnagel G, Maisch B. Prevalence of the parvovirus B19 genome in endomyocardial biopsy specimens. Hum Pathol 2003;34:497-503. abstract.
91. Finkel TH, Török TJ, Ferguson PJ, et al. Chronic parvovirus B19 infection and systemic necrotising vasculitis: opportunistic infection or aetiological agent? Lancet 1994;343:1255-8.
92. Nigro G, Zerbini M, Krzysztofiak A, et al. Active or recent parvovirus B19 infection in children with Kawasaki disease. Lancet 1994;343:1260-1.
93. Ferguson PJ, Saulsbury FT, Dowell SF, Török TJ, Erdman DD, Anderson LJ. Prevalence of human parvovirus B19 infection in children with Henoch-Schönlein purpura. Arthritis Rheum 1996;39:880-1.
94. Gabriel SE, Espy M, Erdman DD, Bjornsson J, Smith TF, Hunder GG. The role of parvovirus B19 in the pathogenesis of giant cell arteritis: a preliminary evaluation. Arthritis Rheum 1999;42:1255-8.
95. Smith SB, Libow LF, Elston DM, Bernert RA, Warschaw KE. Gloves and socks syndrome: early and late histopathologic features. J Am Acad Dermatol 2002;47:749-54.
96. Jacobson SK, Daly JS, Thorne GM, McIntosh K. Clinical parvovirus B19 infection resulting in chronic fatigue syndrome: case history and review. Clin Infect Dis 1997;24:1048-51.
97. Kerr JR, Bracewell J, Laing I, et al. Chronic fatigue syndrome and arthralgia following parvovirus B19 infection. Rheumatology 2002;29:595-602.
98. Kerr JR, Barah F, Chiswick ML, et al. Evidence for the role of demyelination, HLA-DR, alleles, and cytokines in the pathogenesis of parvovirus B19 meningoencephalitis and its sequelae. J Neurol Neurosurg Psychiatry 2002;73:739-46.
99. Barash J, Dushnitzki D, Barak Y, Miron S, Hahn T. Tumor necrosis factor (TNF)alpha and its soluble receptor (sTNFR) p75 during acute human parvovirus B19 infection in children. Immunol Lett 2003;88:109-12.
100. Mortimer PP, Humphries RK, Moore JG, Purcell RH, Young NS. A human parvovirus-like virus inhibits haematopoietic colony formation in vitro. Nature 1983;302:426-9.
101. Potter CG, Potter AC, Hatton CSR, et al. Variation of erythroid and myeloid precursors in the marrow and peripheral blood of volunteer subjects infected with human parvovirus (B19). J Clin Invest 1987;79:1486-92.
102. Ozawa K, Kurtzman G, Young NS. Replication of the B19 parvovirus in human bone marrow cell cultures. Science 1986;233:883-6.
103. Serke S, Schwarz TF, Baurmann H, et al. Productive infection of in vitro generated haemopoietic progenitor cells from normal human adult peripheral blood with parvovirus B19: studies by morphology, immunocytochemistry, flow-cytometry, and DNA-hybridization. Br J Haematol 1991;79:6-13.
104. Yaegashi N, Shiraishi H, Takeshita T, Nakamura M, Yajima A, Sugamura K. Propagation of human parvovirus B19 in primary culture of erythroid lineage cells derived from fetal liver. J Virol 1989;63:2422-6.
105. Brown KE, Anderson SM, Young NS. Erythrocyte P antigen: cellular receptor for B19 parvovirus. Science 1993;262:114-7.
106. Brown KE, Hibbs JR, Gallinella G, et al. Resistance to human parvovirus B19 infection due to lack of virus receptor (erythrocyte P antigen). N Engl J Med 1994;330:1192-6.
107. Srivastava A, Bruno E, Briddell R, et al. Parvovirus B19-induced perturbation of human megakaryocytopoiesis in vitro. Blood 1990;76:1997-2004.
108. O'Sullivan MG, Anderson DC, Fikes JD, et al. Identificafion of a novel simian parvovirus in cynomolgus monkeys with severe anemia: a paradigm of human B19 parvovirus infection. J Clin Invest 1994;93:1571-6.
109. O'Sullivan MG, Anderson DK, Goodrich JA, et al. Experimental infection of cynomolgus monkeys with simian parvovirus. J Virol 1997;71:4517-21.
110. Kurtzman GJ, Platanias L, Lustig L, Frickhofen N, Young NS. Feline parvovirus propagates in cat bone marrow cultures and inhibits hematopoietic colony formation in vitro. Blood 1989;74:71-81.
111. Segovia JC, Gallego JM, Bueren JA, Almendral JM. Severe leukopenia and dysregulated erythropoiesis in SCID mice persistently infected with the parvovirus minute virus of mice. J Virol 1999;73:1774-84.
112. Kurtzman GJ, Cohen BJ, Field AM, Oseas R, Blaese RM, Young NS. The immune response to B19 parvovirus infection and an antibody defect in persistent viral infection. J Clin Invest 1989;84:1114-23.
113. Kajigaya S, Fujii H, Field AM, et al. Self-assembled 1319 parvovirus capsids, produced in a baculovirus system, are antigenically and immunogenically similar to native virions. Proc Natl Acad Sci U S A 1991;88:4646-50.
114. Ballou WR, Reed JL, Noble W, Young NS, Koenig S. Safety and immunogenicity of a recombinant parvovirus B19 vaccine formulated with MF59C.1. J Infect Dis 2003;187:675-8.
115. Bansal GP, Hatfield JA, Dunn FE, et al. Candidate recombinant vaccine for human B19 parvovirus. J Infect Dis 1993;167:1034-44.
116. Saikawa T, Anderson S, Momoeda M, Kajigaya S, Young NS. Neutralizing linear epitopes of B19 parvovirus cluster in the VP1 unique and VP1-VP2 junction regions. J Virol 1993;67:3004-9.
117. Zadori Z, Szelei J, Lacoste MC, et al. A viral phospholipase A2 is required for parvovirus infectivity. Dev Cell 2001;1:291-302.
118. Lunardi C, Tiso M, Borgato L, et al. Chronic parvovirus B19 infection induces the production of anti-virus antibodies with autoantigen binding properties. Eur J Immunol 1998;28:936-48.
119. Erdman DD. Human parvovirus B19: laboratory diagnosis. In: Anderson LJ, Young NS, eds. Human parvovirus B19. Vol. 20 of Monographs in virology. Basel, Switzerland: Karger, 1997:93-104.
120. Zerbini M, Gallinella G, Cricca M, Bonvicini F, Musiani M. Diagnostic procedures in B19 infection. Pathol Biol (Paris) 2002;50:332-8.
121. Anderson MJ, Jones SE, Minson AC. Diagnosis of human parvovirus infection by dot-blot hybridization using cloned viral DNA. J Med Virol 1985;15:163-72.
122. Koch WC, Harger JH, Barnstein B, Adler SP. Serologic and virologic evidence for frequent intrauterine transmission of human parvovirus B19 with a primary maternal infection during pregnancy. Pediatr Infect Dis J 1998;17:489-94.
123. Fairley CK, Smoleniec JS, Caul OE, Miller E. Observational study of effect of intrauterine transfusions on outcome of fetal hydrops after parvovirus B19 infection. Lancet 1995;346:1335-7.
124. Adibo AO, Campbell WA, Feldman D, et al. Resolution of human parvovirus B19-induced nonimmune hydrops after intrauterine transfusion. J Ultrasound Med 1998;17:547-50.
125. Goodear M, Hayward C, Crowther C. Foetal intracardiac transfusion for the treatment of severe anaemia due to human parvovirus B-19 infection. Australas Radiol 1998;42:275-7.
126. Miyamura K, Kajigaya S, Momoeda M, Smith-Gill SJ, Young NS. Parvovirus particles as platforms for protein presentation. Proc Natl Acad Sci U S A 1994;91:8507-11.